Spyre Therapeutics (SYRE) is down -7.4%, or -$2.43 to $30.33.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
- Spyre Therapeutics initiated with an Outperform at Mizuho
- Spyre Therapeutics initiated with a Buy at Citi
- Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls